| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 4 Aug 2025 | 15 Jul 2025 |
| Unichem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2025 inter alia to consider and approve Board Meeting Intimation for Consideration and Approval of Unaudited Financial Results (Consolidated and Standalone) for Quarter Ended June 30 2025 Outcome of Quater ended June 30, 2025 (As Per BSE Announcement Dated on: 04/08/2025) | ||
| Board Meeting | 22 May 2025 | 8 May 2025 |
| Unichem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2025 inter alia to consider and approve Financial results for quarter and year ended March 31 2025 Outcome of Board Meeting (As Per BSE Announcement Dated on 22.05.2025) | ||
| Board Meeting | 28 Mar 2025 | 28 Mar 2025 |
| Outcome of Board Meeting | ||
| Board Meeting | 1 Mar 2025 | 1 Mar 2025 |
| Outcome of Board Meeting - Sale of property | ||
| Board Meeting | 6 Feb 2025 | 14 Jan 2025 |
| UNICHEM LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2025 inter alia to consider and approve unaudited financial results (standalone and consolidated) for the quarter and nine months ended December 31 2024. Unaudited Financial Results (Consolidated & Standalone) for the quarter and nine-months ended 31st December 2024 Included Mr. Uttkarsh Patil, Chief Manufacturing officer - Formulations, as a senior Management Personnel under SEBI LODR Regulations with effect from 6th February 2025 (As Per BSE Announcement dated on 06.02.2025) | ||
| Board Meeting | 13 Nov 2024 | 25 Oct 2024 |
| UNICHEM LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2024 inter alia to consider and approve Unaudited Financial Results for the quarter ended September 30 2024. Unaudited Financial Statements (Consolidated & Standalone) for the second quarter and half year ended 30th September 2024 (As Per BSE Announcement Dated on: 13/11/2024) | ||
Here are some of the stocks that may see significant price movement today: Texmaco Rail, Vedanta, Unichem Laboratories, etc.
Revenue increased by 14.5% to ₹533 crore from ₹466 crore the previous year.
Bayshore Pharmaceuticals is a 100% subsidiary of Unichem Laboratories' parent firm, Ipca Laboratories Ltd.
According to the corporation, the observations have no influence on business continuity or supplies to the US market.
Here are some of the stocks that may see significant price movement today: Hindustan Unilever, Birla Estates, Lupin, etc.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
